NK-1 receptor antagonists for the treatment of neuronal injury and stroke
US6376507B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 18, 1998 |
| Grant date | Apr 23, 2002 |
| Priority date | — |
| Expiry date | Jun 18, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of treating or preventing a disorder selected from stroke, epilepsy, head trauma, spinal cord trauma, ischemic neuronal damage such as cerebral ischemic damage from stroke or vascular occlusion (e.g., during open heart surgery), excitotoxic neuronal damage (e.g., in stroke or epilepsy) and amyotrophic lateral sclerosis in mammals, including humans, using an NK-1 antagonist. It also relates to a method of treating or preventing such disorders in mammals, including humans, using certain quinuclidine derivatives, piperidine derivatives, pyrrolidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds that are substance P receptor antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.